2007
Buts thérapeutiques dans la maladie de Gaucher Therapeutic objectives in Gaucher disease
Mistry P, Germain D. Buts thérapeutiques dans la maladie de Gaucher Therapeutic objectives in Gaucher disease. La Revue De Médecine Interne 2007, 28: 171-175. PMID: 18228683, DOI: 10.1016/s0248-8663(07)78876-8.Peer-Reviewed Original ResearchConceptsGaucher diseaseLife-threatening complicationsStandard of careMaximal clinical benefitRemarkable safety profileTreatment of GDQuality of lifeType 1 GDBone crisesLifelong treatmentClinical benefitSafety profileAsymptomatic phaseTherapeutic goalsDisease evolutionTherapeutic objectivesCareful monitoringLa maladieSkeletal damageNorth American expertsDiseaseDisease phenotypePatientsTreatmentOptimal timeCombined effect of total alkaloids from Feculae Bombycis and natural flavonoids on diabetes
Geng P, Yang Y, Gao Z, Yu Y, Shi Q, Bai G. Combined effect of total alkaloids from Feculae Bombycis and natural flavonoids on diabetes. Journal Of Pharmacy And Pharmacology 2007, 59: 1145-1150. PMID: 17725858, DOI: 10.1211/jpp.59.8.0013.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAlkaloidsAnimalsBlood GlucoseBombyxCholesterolDiabetes Mellitus, ExperimentalDrug SynergismDrug Therapy, CombinationFemaleFlavonoidsGlycoside Hydrolase InhibitorsIntestinal MucosaMaleMedicine, Chinese TraditionalMicePlant ExtractsPlants, MedicinalPostprandial PeriodRatsRats, WistarStarchConceptsInhibiting alpha-glucosidase activityAlpha-glucosidase activityDiabetic mice in vivoMice in vivoBlood glucoseStarch hydrolysateFlavonoidsFasting blood total cholesterolGlucose levelsIn vivoIndividual ingredientsBlood total cholesterolFasting blood glucoseDepressed blood glucose levelsNatural flavonoidPostprandial elevationBlood glucose levelsModel in vitroTherapy of diabetesTAFBShort-term studiesTotal cholesterolOral administrationBombycisBlood
2006
Therapeutic goals in Gaucher disease
Mistry P, Germain DP. Therapeutic goals in Gaucher disease. La Revue De Médecine Interne 2006, 27: s30-s33. PMID: 16644400, DOI: 10.1016/s0248-8663(06)80009-3.Peer-Reviewed Original ResearchConceptsGaucher diseaseTherapeutic goalsType 1 Gaucher diseaseLong-life treatmentLife-threatening complicationsStandard of careRemarkable safety profileQuality of lifeBone crisesPrevent complicationsSafety profileAsymptomatic phaseDisease evolutionCareful monitoringDiseaseSkeletal damageComplicationsPatientsGaucher phenotypeTreatmentOptimal timeTolerabilityAmerican expertsSeverityCare
2002
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Clinical Applications
Holmboe E. Oral Antihyperglycemic Therapy for Type 2 Diabetes: Clinical Applications. JAMA 2002, 287: 373-376. PMID: 11790217, DOI: 10.1001/jama.287.3.373.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiguanidesComorbidityDecision MakingDiabetes Mellitus, Type 2Drug Therapy, CombinationEnzyme InhibitorsEvidence-Based MedicineFemaleGlycoside Hydrolase InhibitorsHumansHypoglycemic AgentsInsulinMaleMiddle AgedPatient Education as TopicPatient ParticipationPhysician-Patient RelationsPractice Guidelines as TopicSulfonylurea CompoundsThiazolesConceptsType 2 diabetesPharmacological treatmentEffective patient self-managementOral antihyperglycemic therapyPharmacological treatment of diabetesPharmacological treatment regimensPatient self-managementOral agentsEvidence-based medicineTreatment regimensAntihyperglycemic therapyMultisystem disorderDiabetic patientsGlycemic controlSelf-managementTreatment of diabetesIndividual patientsPatientsMultidisciplinary carePatient preferencesClinical applicationDiabetesPhysiciansComplex decision makingAgents
2000
Treatment of Gaucher's disease with OGT 918
Mistry P. Treatment of Gaucher's disease with OGT 918. The Lancet 2000, 356: 676. PMID: 10968454, DOI: 10.1016/s0140-6736(00)02618-0.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply